The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
31 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,522,358 in first-year total cost, median $444,969.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-A (J1)]8
- Special Emphasis Panel[ZCA1 SRB-K (M2)]8
- Special Emphasis Panel[ZCA1 SRB-A (M1)]5
- Special Emphasis Panel[ZCA1 SRB-K (J1)]4
- Special Emphasis Panel[ZCA1 SRB-5 (J2)]3
Most frequent institutions
- DANA-FARBER CANCER INST3
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE2
- THOMAS JEFFERSON UNIVERSITY2
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
- YALE UNIVERSITY2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | (8) Genetics of Immune Related Adverse Events and Response to Immunotherapy1R01CA227466-01 | ZIV, ELAD | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $699,062 | ZCA1 |
| 2018 | (PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactions1R01CA227237-01 | GUSEV, ALEXANDERZAITLEN, NOAH A | DANA-FARBER CANCER INST, MA | $686,519 | ZCA1 |
| 2018 | (PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses1R01CA216101-01A1 | KAECH, SUSAN MSHADEL, GERALD | SALK INSTITUTE FOR BIOLOGICAL STUDIES, CA | $670,933 | ZCA1 |
| 2018 | (PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS1R01CA230712-01 | JENKINS, ROBERT B. | MAYO CLINIC ROCHESTER, MN | $633,992 | ZCA1 |
| 2018 | (8) Genomic determinants of the T-cell regulome in immune checkpoint blockade1R01CA227505-01 | KIRCHHOFF, TOMASWEBER, JEFFREY S | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $620,860 | ZCA1 |
| 2018 | (PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy1R01CA231325-01 | CURIEL, TYLER J.SHEN-ORR, SHAI SHLOMO | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $582,917 | ZCA1 |
| 2018 | (8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors1R01CA227473-01 | HEROLD, KEVAN CKLUGER, HARRIET M. | YALE UNIVERSITY, CT | $580,767 | ZCA1 |
| 2018 | (PQ4) Novel tools for in vivo study of genetic interactions in cancer progression1R01CA231112-01 | CHEN, SIDI | YALE UNIVERSITY, CT | $576,627 | ZCA1 |
| 2018 | (PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma1R01CA219850-01A1 | DANIAL, NIKA NMARTO, JARROD A. | DANA-FARBER CANCER INST, MA | $558,022 | ZCA1 |
| 2018 | (PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors1R01CA231291-01 | ATKINS, MICHAEL BENJAMINWELLSTEIN, ANTON | GEORGETOWN UNIVERSITY, DC | $533,211 | ZCA1 |
| 2018 | (PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance1R01CA231283-01 | LIPKIN, STEVEN M | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $501,220 | ZCA1 |
| 2018 | (PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition1R01CA231295-01 | OSMAN, IMANWEBER, JEFFREY S | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $481,288 | ZCA1 |
| 2018 | (PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivo1R01CA231253-01 | PETROV, DMITRIWINSLOW, MONTE MEIER | STANFORD UNIVERSITY, CA | $471,700 | ZCA1 |
| 2018 | (PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)1R01CA231267-01 | FEHRENBACHER, JILL CKELLEY, MARK R. | INDIANA UNIVERSITY INDIANAPOLIS, IN | $460,814 | ZCA1 |
| 2018 | (PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy1R01CA219871-01A1 | FACCIABENE, ANDREAKOUMENIS, CONSTANTINOS | UNIVERSITY OF PENNSYLVANIA, PA | $451,326 | ZCA1 |
| 2018 | Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer1R01CA231219-01 | ARONSON, WILLIAM JCOHEN, PINCHAS | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $444,969 | ZCA1 |
| 2018 | (PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis1R01CA230848-01 | FU, LONING NONEMOORE, DAVID D | BAYLOR COLLEGE OF MEDICINE, TX | $442,560 | ZCA1 |
| 2018 | (PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome1R01CA219896-01A1 | WARGO, JENNIFER A. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $429,943 | ZCA1 |
| 2018 | (PQ 12) Targeting SMPDL3b to Prevent Radiation-Induced Nephrotoxicity1R01CA227493-01 | FORNONI, ALESSIAMARPLES, BRIAN | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $427,990 | ZCA1 |
| 2018 | (PQ5) Relevance of VDAC2 heterogeneity for hepatic tumor growth and targeting1R01CA216254-01A1 | HAJNOCZKY, GYORGY | THOMAS JEFFERSON UNIVERSITY, PA | $413,916 | ZCA1 |
| 2018 | Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors1R01CA227388-01 | VAN ALLEN, ELIEZER M | DANA-FARBER CANCER INST, MA | $407,175 | ZCA1 |
| 2018 | (PQ1) The role of cell-to-cell variation in the penetrance of heritable mutant RAS hypodermal neoplasias1R01CA219460-01A1 | MENDENHALL, ALEXANDER RICHARD | UNIVERSITY OF WASHINGTON, WA | $397,573 | ZCA1 |
| 2018 | TP53 Germline Mutations: Beyond LFS1R01CA219556-01A1 | LI, YONG | CLEVELAND CLINIC LERNER COM-CWRU, OH | $377,037 | ZCA1 |
| 2018 | (PQ4) - Tools for simultaneous disruption of multiple epigenetically silenced genes for studying their roles in tumorigenesis using ex vivo human and mouse colon organoid and in vivo mouse models1R01CA230995-01 | BAYLIN, STEPHEN B.EASWARAN, HARIHARAN | JOHNS HOPKINS UNIVERSITY, MD | $374,578 | ZCA1 |
| 2018 | PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain1R01CA227064-01 | HEIJNEN, COBI JKAVELAARS, ANNEMIEKE | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $366,766 | ZCA1 |
| 2018 | Exosomes and platinum-induced peripheral neuropathy1R01CA219829-01A1 | ZHANG, ZHENG GANG | HENRY FORD HEALTH SYSTEM, MI | $358,545 | ZCA1 |
| 2018 | (11) Diet Modification to Augment Radiation for Breast Cancer Brain Metastases1R01CA227479-01 | SIMONE, NICOLE L | THOMAS JEFFERSON UNIVERSITY, PA | $351,726 | ZCA1 |
| 2018 | PQ2 Obesity-induced fibrocytes promote breast cancer progression1R01CA227542-01 | ARENDT, LISA M | UNIVERSITY OF WISCONSIN-MADISON, WI | $349,988 | ZCA1 |
| 2018 | Genomic Prediction of Doxorubicin-Induced Cardiotoxicity1R01CA220002-01A1 | BURRIDGE, PAUL W.STRANGER, BARBARA E | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $339,052 | ZCA1 |
| 2018 | (PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy1R01CA219637-01A1 | DAMAJ, M. IMADGEWIRTZ, DAVID A. | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $281,441 | ZCA1 |
| 2018 | (PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer1R01CA230854-01 | JIN, JIANPARSONS, RAMON E | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $249,841 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-11-0.1.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.